Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

OBJECTIVES: This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, J S, Emery, P, Ferraccioli, G F, Samborski, W, Berenbaum, F, Davies, O R, Koetse, W, Purcaru, O, Bennett, B, Burkhardt, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392224/
https://www.ncbi.nlm.nih.gov/pubmed/24431394
http://dx.doi.org/10.1136/annrheumdis-2013-204632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392224/
https://www.ncbi.nlm.nih.gov/pubmed/24431394
http://dx.doi.org/10.1136/annrheumdis-2013-204632

Ejemplares similares